Astrazeneca Comments On Fda Joint Advisory Committee Meeting On Post-marketing Safety Studies For The Use Of Labas In Asthma

NepalNational.com		Thursday 9th February 2012	Issue 20120209
			Follow us on

	More Breaking Health News
	Let Syrians decide their future themselves, says Russia
	In unprecedented move, Iranian parliament summons president for questioning
	Argentina to approach UN on dispute with UK over Falklands
	Santorum wins in three state caucuses, breaks Romney's winning streak
	Pre-dawn drone attack kills 10 militants in Pakistan
	Settlement reached in 15 more phone hacking cases
	In 2011 German exports edged past trillion euros mark
	Shareholders force Yahoo board shake up
	Aviation safety agency orders inspection of entire A380 fleet
	Weaker commodities price see BHP Billiton profits dip
	Unremarkable moves on Wall Street
	Not giving up music career: Hudgens


Get Breaking Health News headlines emailed to you daily.

Astrazeneca Comments On Fda Joint Advisory Committee Meeting On Post-marketing Safety Studies For The Use Of Labas In Asthma
Source: Medical News Today
Friday 12th March, 2010

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees ... ...

Read the full story at Medical News Today

Share this page

Email this story to a friend

Have your say on this story